An interventional study of Digital: Kiso Mind App in Psychosis, Psychotic Disorders and Primary Psychotic Disorders, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Psychotic Disorders with a site in Germany — 19 open to participants now, 21 under way, 4 of them phase 3. Psychotic Disorders · Germany.
Among the 72 studies in Psychotic Disorders with a site in Germany, this one is the 42nd largest by planned enrollment of the 65 interventional ones that give a count, is one of 6 that started in 2026, is one of 33 with no phase, reaches primary completion later than 8 of the 20 other live ones, and was the 69th registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →19 of the 72 studies in Psychotic Disorders with a site in Germany are open now. Recruiting first, the newest first:
University of Oxford · Sites in Germany, Austria, Greece and 6 more countries
Ages 16–40
Stephanie Mehl · Sites in Germany
Ages 16–35
Charite University, Berlin, Germany · Sites in Germany
Ages 18–65
Technical University of Munich · Sites in Germany
Ages 18+
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in Germany, United States, Argentina and 22 more countries
Ages 55–90
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 85 across the 65 interventional studies, 360 across the 7 observational. Of the 41 that completed or were terminated, 8 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 72 have an industry lead sponsor. The 10 most frequent:
Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.
Charite University, Berlin, Germany has 9 studies filed under Psychotic Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Psychotic Disorders with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT05905003Brigham and Women's HospitalAMP SCZ® Observational Study: PREDICT-DPACC | 2027-04-30 |
| NCT07455929Charite University, Berlin, GermanyFeasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 72 studies in Psychotic Disorders with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Kiso pilot study is a randomized controlled trial to test the acceptability and feasibility of a novel digital intervention, namely the Kiso Mind smartphone app. A parallel-group design is utilized. Participants either receive access to the Kiso Mind intervention and treatment-as-usual (TAU) in the experimental condition or receive treatment as usual (TAU) in the control condition. The intervention is designed for participants diagnosed with either schizophrenia (F20.0) or schizoaffective disorder (F25.0) according to the ICD-10.
To examine acceptability, feasibility, and preliminary effectiveness, both self-report and rater-based assessments are administered at baseline (T0) and at the end of the 12-week intervention period (post-intervention T1). Lastly, a qualitative interview will be conducted with participants from the experimental condition. The primary outcome of the present study is the acceptability and feasibility of the Kiso Mind app. The secondary outcome consists of general psychopathology, and positive-, negative-, depressive symptoms, as well as social functioning and self-efficacy ratings.
There are multiple ways to join the present study. Healthcare workers at different institutions across Germany identify eligible participants and invite them to participate in the study. Those institutions include inpatient wards and outpatient facilities. Moreover, participants can join via multiple channels, including online channels and advertising such as social media, etc. Eligibility screenings and baseline clinician ratings are conducted centrally by research associates (psychologists) at Charité Universitätsmedizin Berlin via a video interview. After confirming the inclusion criteria, participants will be randomised and receive the self-report section of the baseline assessment. Randomization is conducted independently by research associates at the Universitätsklinikum Hamburg-Eppendorf in Hamburg. After 12 weeks, participants complete a clinical interview to assess the rater-based section of the post-treatment assessment and receive the self-report section via email.
All participant data is stored in a pseudonymized format. No clinical data is saved in combination with clinical data. The participants have the right to access their data and the right to claim deletion of their data. Data are stored in an online database, accessible only to researchers involved in the study.
Due to the exploratory nature of this study, we aim to recruit 60 to 80 participants in total until June.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The intervention comprises a 12-week digital intervention containing several psychoeducation modules as well as a broad variety of evidence-based psychotherapeutic modules based on CBTp principles. In addition, the digital intervention includes functions to assist with daily challenges, such as medication reminders, mood trackers and emergency contacts.
Behavioral: Digital: Kiso Mind App
with Schizophrenia or Schizoaffective Disorder in Germany consists of quarterly psychiatric appointments for psychopharmacological treatment. Psychotherapy is typically limited to one appointment a month, in very rare cases multiple appointments a month.
See above.
Proportion of PP receiving threshold dose (Acceptability)
The proportion of modules completed on average by all participants.
Time frame: 12 weeks
Nr. of pp willing to participate (Feasibility)
The number of eligible participants, that are willing to participate in Kiso (recruitment)
Time frame: 12 weeks
Clinical Global Impression (T0; T1)
Assesses overall clinical illness severity as judged by the clinician, providing a global rating of the patient's current level of psychopathology. (Scores: 1 to 7; higher scores = higher illness severity)
Time frame: 12 weeks
Patient Global Impression (T0; T1)
Description: Assesses overall clinical illness severity as judged by the patients, providing a global rating of the patient's perceived current level of psychopathology. (Scores: 1 to 5; higher scores = higher perceived illness severity)
Time frame: 12 weeks
Community Assessment of Psychic Experiences (CAPE) (T0, T1)
Assesses the frequency and distress associated with psychotic-like experiences in the general population, covering positive, negative, and depressive symptom dimensions. (Scores: 0 to 96; higher scores = higher frequency of psychotic-like experiences AND Scores: 0 to 96; higher scores = higher distress of psychotic like experiences)
Time frame: 12 weeks
Beck Depressions-Inventar (BDI-II) (T0, T1)
A 21-item self-report questionnaire measuring the severity of depressive symptoms over the past two weeks. (Scores: 0 to 63; higher scores = higher severity of depressive symptoms)
Time frame: 12 weeks
Brief Symptom Inventory (BSI) (T0, T1)
A self-report measure assessing general psychological distress across multiple symptom domains (e.g., depression, anxiety, somatization). (Scores: 0 to 212; higher scores = higher self-reported general psychological distress)
Time frame: 12 weeks
General Self-Efficacy Scale (GSE) (T0, T1)
Measures perceived self-efficacy, reflecting an individual's belief in their ability to cope with difficult demands and challenges. (Scores: 4 to 40; higher scores = higher self-efficacy)
Time frame: 12 weeks
Social Functioning Scale (SFS) (T0, T1)
Assesses social functioning and role performance, including social engagement, interpersonal behavior, and independent living skills.
Time frame: 12 weeks
EQ-5D Quality of life questionnaire (T0, T1)
A standardized measure of health-related quality of life, covering mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. (Scores: 5 to 25; higher scores = lower health-related quality of life)
Time frame: 12 weeks
Patient Satisfaction Questionnaire (ZUF-8) (T1, Experimental Group)
Evaluates patient satisfaction with treatment or services, focusing on perceived quality, usefulness, and overall satisfaction. (Scores: 4 to 28; higher scores = higher patient satisfaction)
Time frame: 12 weeks
System Usability Scale (SUS) (T1, Experimental Group)
A 10-item questionnaire assessing perceived usability and user-friendliness of a system or digital intervention.
Time frame: 12 weeks
Negative Effects Questionnaire (NEQ) (T1, Experimental Group)
Assesses adverse and unwanted effects of psychological treatment, including symptom worsening, dependency, or emotional distress. (Scores: 0 to 116; higher scores = higher severity of unwanted effects)
Time frame: 12 weeks
Medication Adherence Report Scale (MARS-5) (T0, T1)
A self-report measure assessing medication adherence behavior, including intentional and unintentional non-adherence. (Scores: 5 to 25; higher scores = higher medication non-adherence)
Time frame: 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jun 2026, 5 months after the start.
Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 5 months is below that.
Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charite University, Berlin, Germany →